Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11992637 | 1.00 | P2RY12 (0.56) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14113266 | 1.00 | P2RY12 (0.56) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL24687158 | 1.00 | P2RY12 (0.56) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22402681 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21504639 | 0.92 | PI4KA (0.52) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29444514 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16378775 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22601403 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30827092 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1097616 | 0.92 | PI4KA (0.62) | P2RY12PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS | 2015-08-20 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
| WO-2007022506-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022470-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | P2RY12 4418/4885PI4KA 3279/4885PI4K2B 2847/4885 |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | P2RY12 3442/4885PI4KA 2920/4885PI4K2B 2760/4885 |
| US-20150232840-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | P2RY12 3442/4885PI4KA 2920/4885PI4K2B 2760/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | P2RY12 3442/4885PI4KA 2920/4885PI4K2B 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.